Is second line aflibercept and FOLFIRI a tolerable and useful down-staging schedule in Ras mutant advanced colorectal cancer in a real world environment?

Trial Profile

Is second line aflibercept and FOLFIRI a tolerable and useful down-staging schedule in Ras mutant advanced colorectal cancer in a real world environment?

Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Oct 2015

At a glance

  • Drugs Aflibercept (Primary) ; Fluorouracil; Folinic acid; Irinotecan
  • Indications Colorectal cancer; Liver metastases
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Oct 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top